Sandoz Group AG, the Swiss generics and biosimilar medicines’ company, has nominated Graeme Pitkethly to its board of directors to lead the company’s audit, risk and compliance committee. The appointment is expected to take effect after Sandoz’s annual general meeting on 30 April. Mr Pitkethly is an experienced executive having served as chief financial officer at Unilever Plc for 21 years until December 2023. Earlier in his career he held senior corporate finance roles in the telecommunications industry.
Sandoz, formerly a division of Novartis, became an independent company on 4 October 2023. It is listed on the SIX Swiss Exchange in Zurich. It has a portfolio of more than 1,500 products that address diseases from the common cold to cancer. Among its breakthroughs is the development of the first oral penicillin in 1951 and the first biosimilar medicine in 2006. Sandoz announced the appointment on 1 February 2024.
Copyright 2024 Evernow Publishing Ltd